Pharmaceutical patents are legal rights granted to inventors or companies that provide exclusive rights to produce and sell their innovation for a specified time.

Oncternal Therapeutics has released new information regarding its ongoing early to mid-stage clinical trial of ONCT-808, a CAR T therapy aimed at ROR1, for individuals facing recurring or hard-to-treat aggressive B-cell lymphoma.

Biologic exclusivity conveys 12 years of total market protection.

Drastically cut down patent review times by focusing on the most relevant claim. Drug patent searches now allow you to identify the exact claim location of your hit sequences and the accompanying claim text directly from the results page!

RayzeBio's RYZ101 targets SSTR2, often overexpressed in GEP-NETs and extensive stage small cell lung cancer.

TLR agonists are substances that activate the Toll-like receptor, enhancing the immune response against pathogens.

Coherus has revealed that UDENYCA ONBODY™, an innovative and advanced technology for administering pegfilgrastim-cbqv, has received authorization from the FDA.

Protein sulfation is a post-translational modification, where a sulfate group gets added to a specific amino acid residue in a protein.

Chugai Pharma announced preclinical results for their antibody, DONQ52, published in Nature Communications.

Fast track designation (FTD) is a process used by the U.S. Food and Drug Administration (FDA) tofacilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

LegoChem Biosciences announced a licensing deal with Janssen Biotech to develop and market LCB84, a Trop2-targeted antibody-drug conjugate.

5-HT1A receptor agonists are drugs that activate the 5-HT1A receptor, used in treating conditions like anxiety, depression, and schizophrenia.